Status: Recruiting
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and initial efficacy.
Participants needed: 15
Trial details
Phase: Early Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: Xiaorong SunUpdated: Jan 14, 2026Locations: 1
Eligibility criteria
Voluntary participation in the study and signing of the informed consent form. [+7]
Patients who received radiotherapy (except palliative radiotherapy) or chemother... [+9]